Who are Propranolol+pyridostigmine's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/propranolol-pyridostigmine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Propranolol+pyridostigmine — Competitive Intelligence Brief

Propranolol+pyridostigmine (Propranolol+pyridostigmine) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Beta-blocker + Acetylcholinesterase inhibitor combination. Area: Neurology; Cardiovascular.

marketed Beta-blocker + Acetylcholinesterase inhibitor combination Beta-adrenergic receptors; Acetylcholinesterase Neurology; Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Propranolol+pyridostigmine (Propranolol+pyridostigmine) — Seoul National University Hospital. Propranolol blocks beta-adrenergic receptors to reduce heart rate and blood pressure, while pyridostigmine inhibits acetylcholinesterase to increase acetylcholine levels and enhance neuromuscular transmission.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Propranolol+pyridostigmine TARGET	Propranolol+pyridostigmine	Seoul National University Hospital	marketed	Beta-blocker + Acetylcholinesterase inhibitor combination	Beta-adrenergic receptors; Acetylcholinesterase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Beta-blocker + Acetylcholinesterase inhibitor combination class)

Seoul National University Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Propranolol+pyridostigmine — Competitive Intelligence Brief. https://druglandscape.com/ci/propranolol-pyridostigmine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab